Medtronic, Inc.'s New Endeavor(R) Zotarolimus-Eluting Stent Approved for Patients with Coronary Artery Disease in Canada

MISSISSAUGA, Canada & MINNEAPOLIS--(BUSINESS WIRE)--Medtronic of Canada Ltd. announced today that Medtronic, Inc. (NYSE:MDT), has received regulatory approval from Health Canada’s Therapeutic Products Directorate (TPD) for use of the Endeavor drug-eluting coronary stent (DES) system in the treatment of coronary artery disease. The company expects to begin commercial sales of the Endeavor stent in Canada by the end of March.

Back to news